• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,988.68 -122.56
( -0.16%)
Global Indices
Nasdaq
48,485.12 -71.88
(-0.15%)
Dow Jones
7,044.29 55.91
(0.80%)
Hang Seng
59,591.25 1,457.01
(2.51%)
Nikkei 225
10,572.50 -36.56
(-0.34%)
Forex
USD-INR
93.24 -0.60
(-0.63%)
EUR-INR
109.88 0.00
(0.00%)
GBP-INR
126.32 0.15
(0.12%)
JPY-INR
0.59 0.00
(-0.22%)

EQUITY - MARKET SCREENER

Karur Vysya Bank Ltd
Industry :  Banks - Private Sector
BSE Code
ISIN Demat
Book Value()
590003
INE036D01028
132.3979366
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
KARURVYSYA
11.77
27047.72
EPS(TTM)
Face Value()
Div & Yield %
23.78
2
0.77
 

Dr Reddy's Lab gets EIR from USFDA for Srikakulam facility
Mar 06,2026
The USFDA classified the inspection outcome as “Voluntary Action Indicated” (VAI) and confirmed that the inspection has been officially closed under 21 CFR 20.64(d)(3).

The inspection included both a Good Manufacturing Practice (GMP) review and a Pre-Approval Inspection (PAI) conducted at the company’s FTO-SEZ PU01 facility. The company had earlier informed about the USFDA inspection on 12 December 2025.

Hyderabad-based Dr Reddy’s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

Dr Reddy’s Laboratories reported a 14.4% decline in consolidated net profit to Rs 1,209.8 crore despite a 4.4% jump in revenue to Rs 8,716.8 crore in Q3 FY26 over Q3 FY25.

The counter shed 0.91% to Rs 1,301.10 on the BSE.